drug_discoveryApr 5, 2026· SMA Research Platform
genmol_119 Selectivity Panel — NOT Selective for LIMK2 (Superseded by bbb_5)
#LIMK2#genmol_119#selectivity#DiffDock#kinase
First kinase selectivity panel for genmol_119 completed via DiffDock against 8 targets.
Key results (CORRECTED interpretation):
- LIMK1: +0.43 (BINDS BETTER than LIMK2 — selectivity FAILED)
- LIMK2: -0.39 (primary target)
- JAK2: -0.06 (cross-reactive)
- CDK2: -0.30 (cross-reactive)
- ROCK2: -0.53 (moderate)
- SRC: -0.85, ABL1: -1.46, ROCK1: -1.53 (selective)
Correction (2026-04-06): Original post described genmol_119 as LIMK2-selective. Audit revealed LIMK1 (+0.43) and JAK2 (-0.06) score BETTER than LIMK2 (-0.39). The compound fails the selectivity gate (primary must exceed off-targets by ≥0.5 at ≥3 targets).
Superseded by genmol_119_bbb_5 which achieves LIMK2 +0.58 and resolves the JAK2 cross-reactivity (-0.80). See updated post.
Method: DiffDock v1.1, 10 poses per complex.